Download PDF
Synlett
DOI: 10.1055/a-2564-4559
Perspectives

Quinoline based FDA Approved Drugs: Synthetic Route and Clinical Uses

Devesh Chandra
1   Chemical Technology, CSIR-IHBT, Palampur, India (Ringgold ID: RIN29065)
,
Sachin Sachin
1   Chemical Technology, CSIR-IHBT, Palampur, India (Ringgold ID: RIN29065)
,
Shourabh Rav 
2   Chemical Technology Division, CSIR - Institute of Himalayan Bioresource Technology, Palampur, India (Ringgold ID: RIN29065)
,
Upendra Sharma
3   Chemical Technology Division, CSIR-IHBT, Palampur, India (Ringgold ID: RIN29065)
› Author Affiliations
› Further Information
  PDF Download All articles of this category

Abstract In the last 25 years, the U.S. Food and Drug Administration (FDA) approved 11 new molecular entities (NMEs) comprising quinoline as core moiety. These drugs are primarily used for the treatment of anemia, malaria, hepatitis, and various types of cancer, i.e., lung, breast, kidney, and blood cancer and thyroid. Based on their approval date, a chronological discussion on these marketed drugs is provided. This review summarized the industrial synthesis, mechanism of action and clinical uses of the quinoline-based FDA-approved NMEs 21st century.



Publication History

Received: 22 January 2025

Accepted after revision: 21 March 2025

Accepted Manuscript online:
21 March 2025

© . Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany